DXC017

DXC017 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Hangzhou DAC Biotech for the treatment of solid tumors. As an ADC, DXC017 is designed to leverage the specificity of a monoclonal antibody to deliver a potent cytotoxic agent directly to tumor cells, thereby increasing therapeutic efficacy while reducing off-target effects. While the specific molecular target of the antibody component and the nature of the cytotoxic payload have not been publicly disclosed by the developer, the candidate is part of Hangzhou DAC Biotech's extensive pipeline of ADC therapies that utilize proprietary linker and payload technologies. The drug is currently undergoing preclinical evaluation to determine its safety and efficacy profile prior to potential clinical trial initiation.